# Clinical Trials Data EGFR - Document 6

# S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01693419

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Pathologically confirmed locally advanced unresectable, recurrent or metastatic adenocarcinoma of pancreas (Stage III-IV ; TNM staging system)\n\* Measurable or evaluable disease by RECIST criteria 1.1\n\* Minimum age of 18 years\n\* ECOG Performance status 0-1\n\* Prior adjuvant chemotherapy without gemcitabine, erlotinib or S-1 is allowed if more than 4 weeks elapsed since completion of chemotherapy.\n\* More than 4 weeks since completion of prior radiotherapy (measurable or evaluable lesions should be outside the radiation field)\n\* Adequate organ functions\n\* Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital.\n\nExclusion Criteria:\n\n\* Patients treated previously with gemcitabine, erlotinib, or S-1 as adjuvant chemotherapy.\n\* Patients with CNS metastases\n\* Patients with active infection, severe heart disease, uncontrollable hypertension or diabetes mellitus, myocardial infarction during the preceding 6 months, pregnancy, or breast feeding\n\* Any previous or concurrent malignancy other than non-melanoma skin cancer or in situ cancer of uterine cervix\n\* Known history of cerebral or leptomeningeal metastases or neurologic disease",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, there is no mention of exclusion due to a specific genetic mutation such as an EGFR gene mutation. The primary eligibility and exclusion criteria focus on the patient's cancer stage, prior treatments, organ function, and certain health conditions.  
  
Therefore, a patient with an EGFR gene mutation would potentially be eligible for this clinical trial, as long as they meet all other inclusion and exclusion criteria outlined. It's important for the patient to discuss with their healthcare provider and the clinical trial team to ensure all aspects of eligibility are considered.